



## Vaccine Adjuvants

Take your vaccine to the next level

InVivoGen



## Corrections

*J Immunol* 2010; 184:1121; ;  
doi: 10.4049/jimmunol.0990112  
<http://www.jimmunol.org/content/184/2/1121>

This information is current as  
of May 17, 2021.

### Why *The JI*? [Submit online.](#)

- **Rapid Reviews! 30 days\*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

*\*average*

**Subscription** Information about subscribing to *The Journal of Immunology* is online at:  
<http://jimmunol.org/subscription>

**Permissions** Submit copyright permission requests at:  
<http://www.aai.org/About/Publications/JI/copyright.html>

**Email Alerts** Receive free email-alerts when new articles cite this article. Sign up at:  
<http://jimmunol.org/alerts>

*The Journal of Immunology* is published twice each month by  
The American Association of Immunologists, Inc.,  
1451 Rockville Pike, Suite 650, Rockville, MD 20852  
Copyright © 2010 by The American Association of  
Immunologists, Inc. All rights reserved.  
Print ISSN: 0022-1767 Online ISSN: 1550-6606.



## Corrections

Li, X., T. Shiratsuchi, G. Chen, P. Dellabona, G. Casorati, R. W. Franck, and M. Tsuji. 2009. Invariant TCR rather than CD1d shapes the preferential activities of C-glycoside analogues against human versus murine invariant NKT cells. *J. Immunol.* 183: 4415–4421.

In Fig. 4A, the unit of measurement for the concentration of glycolipids and IC50 was incorrectly stated as nM. The unit of measurement should be  $\mu$ M.

[www.jimmunol.org/cgi/doi/10.4049/jimmunol.0990112](http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.0990112)